

Biomarkers and tumour heterogeneity: Friends or enemies for differential therapy?

Joint meeting of the EAU Section of Urological Pathology (ESUP) and the EAU Section of Urological Research (ESUR)

Saturday, 25 March
10:15 - 14:00

Location: Room Paris, North Hall (Level 1)

Chairs: K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)

Aims and objectives of this session

Major advances have been made in understanding the mechanisms of primary and acquired resistance to current agents in urogenital cancer, as well as in the identification and validation of relevant molecular targets. The integration of clinic-pathologic data with emerging techniques of molecular profiling-based treatment will represent the future of personalised therapeutic approach for urogenital cancer.

10:15 - 10:20

Welcome and introduction

K. Junker, Homburg (DE)

10:20 - 10:50

Biomarkers: Introduction

Moderators: L. Kiemeny, Nijmegen (NL)
R. Montironi, Ancona (IT)

10:20 - 10:35

Biomarkers: Definition, requirements, pitfalls

L. Kiemeny, Nijmegen (NL)

10:35 - 10:50

Best biomarkers in body fluids: CTC's, free DNA/RNA or exosomes?

S. Riethdorf, Hamburg (DE)

10:50 - 11:40

Bladder cancer

Moderators: M. Knowles, Leeds (GB)
A. Lopez-Beltran, Lisbon (PT)
A. Vlahou, Athens (GR)

10:50 - 11:00

Histopathological subtypes: Prognostic relevance

A. Lopez-Beltran, Lisbon (PT)

11:00 - 11:10

Basal/luminal signature: Identification of aggressive subtypes

Y. Allory, Creteil (FR)

11:10 - 11:20

Non-muscle invasive cancer: BCG therapy prediction

A.M. Kamat, Houston (US)

11:20 - 11:30

Muscle-invasive cancer: Can we predict the response to systematic therapy?

T. Powles, London (GB)

11:30 - 11:40

Introduction of new markers to clinical guidelines and practice: Requirements and roadmap

B.W.G. Van Rhijn, Amsterdam (NL)

11:40 - 12:30	Kidney cancer Moderators: Y. Allory, Creteil (FR) V. Ficarra, Udine (IT) H. Moch, Zurich (CH)
11:40 - 11:50	Relevance of histopathological subtypes: Which are the bad guys? H. Moch, Zurich (CH)
11:50 - 12:00	Prognostic markers: Ready to use? K. Junker, Homburg (DE)
12:00 - 12:10	Predictive markers E. Oosterwijk, Nijmegen (NL)
12:10 - 12:20	Genetic heterogeneity: What is relevant concerning marker development? S. Turajlic, London (GB)
12:20 - 12:30	Heterogeneity: The urologist's view V. Ficarra, Udine (IT)

12:30 - 13:00	Penile and testicular cancer Moderators: G. Netto, Baltimore (US) To be confirmed
12:30 - 12:40	Biomarkers for testicular cancer: What we have and what we need L. Looijenga, Rotterdam (NL)
12:40 - 12:50	The new 2016 WHO classification of penile cancer M. Colecchia, Milan (IT)
12:50 - 13:00	Penile cancer: What we need and what we have - The urologist's view S. Horenblas, Amsterdam (NL)

13:00 - 13:50	Prostate cancer Moderators: H.Y. Leung, Glasgow (GB) R. Montironi, Ancona (IT) G. Van Der Pluijm, Leiden (NL)
13:00 - 13:10	Implementation of the new 'prostate cancer grading system' R. Montironi, Ancona (IT)
13:10 - 13:20	A new classification framework for human prostate cancer C. Cooper, Sutton, Surrey (GB)
13:20 - 13:30	Tumour heterogeneity: The urologist's view A.S. Bjartell, Malmö (SE)
13:30 - 13:40	Predictive markers in prostate cancer: Tissue based markers G. Netto, Baltimore (US)
13:40 - 13:50	Predictive markers in prostate cancer: Liquid biopsy

To be confirmed

13:50 - 14:00

Conclusion

R. Montironi, Ancona (IT)